BACKGROUND: Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation. METHODS: We analyzed overall mortality, mortality not preceded by relapse, recurrent malignant conditions, and the frequency and severity of major complications of transplantation, including graft-versus-host disease (GVHD) and hepatic, renal, pulmonary, and infectious complications, among 1418 patients who received their first allogeneic transplants at our center in Seattle in the period from 1993 through 1997 and among 1148 patients who received their first allogeneic transplants in the period from 2003 through 2007. Components of the Pretransplant Assessment of Mortality (PAM) score were used in regression models to adjust for the severity of illness at the time of transplantation. RESULTS: In the 2003-2007 period, as compared with the 1993-1997 period, we observed significant decreases in mortality not preceded by relapse, both at day 200 (by 60%) and overall (by 52%), the rate of relapse or progression of a malignant condition (by 21%), and overall mortality (by 41%), after adjustment for components of the PAM score. The results were similar when the analyses were limited to patients who received myeloablative conditioning therapy. We also found significant decreases in the risk of severe GVHD; disease caused by viral, bacterial, and fungal infections; and damage to the liver, kidneys, and lungs. CONCLUSIONS: We found a substantial reduction in the hazard of death related to allogeneic hematopoietic-cell transplantation, as well as increased long-term survival, over the past decade. Improved outcomes appear to be related to reductions in organ damage, infection, and severe acute GVHD. (Funded by the National Institutes of Health.).
BACKGROUND: Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation. METHODS: We analyzed overall mortality, mortality not preceded by relapse, recurrent malignant conditions, and the frequency and severity of major complications of transplantation, including graft-versus-host disease (GVHD) and hepatic, renal, pulmonary, and infectious complications, among 1418 patients who received their first allogeneic transplants at our center in Seattle in the period from 1993 through 1997 and among 1148 patients who received their first allogeneic transplants in the period from 2003 through 2007. Components of the Pretransplant Assessment of Mortality (PAM) score were used in regression models to adjust for the severity of illness at the time of transplantation. RESULTS: In the 2003-2007 period, as compared with the 1993-1997 period, we observed significant decreases in mortality not preceded by relapse, both at day 200 (by 60%) and overall (by 52%), the rate of relapse or progression of a malignant condition (by 21%), and overall mortality (by 41%), after adjustment for components of the PAM score. The results were similar when the analyses were limited to patients who received myeloablative conditioning therapy. We also found significant decreases in the risk of severe GVHD; disease caused by viral, bacterial, and fungal infections; and damage to the liver, kidneys, and lungs. CONCLUSIONS: We found a substantial reduction in the hazard of death related to allogeneic hematopoietic-cell transplantation, as well as increased long-term survival, over the past decade. Improved outcomes appear to be related to reductions in organ damage, infection, and severe acute GVHD. (Funded by the National Institutes of Health.).
Authors: George B McDonald; John T Slattery; Michelle E Bouvier; Song Ren; Ami L Batchelder; Thomas F Kalhorn; H Gary Schoch; Claudio Anasetti; Ted Gooley Journal: Blood Date: 2002-10-24 Impact factor: 22.113
Authors: Takahiro Fukuda; Michael Boeckh; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Paul J Martin; Rainer F Storb; Kieren A Marr Journal: Blood Date: 2003-04-10 Impact factor: 22.113
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: J Storek; M A Dawson; B Storer; T Stevens-Ayers; D G Maloney; K A Marr; R P Witherspoon; W Bensinger; M E Flowers; P Martin; R Storb; F R Appelbaum; M Boeckh Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: Morgan Hakki; Stanley R Riddell; Jan Storek; Rachel A Carter; Terry Stevens-Ayers; Patrick Sudour; Kristen White; Lawrence Corey; Michael Boeckh Journal: Blood Date: 2003-07-03 Impact factor: 22.113
Authors: Todd D Freudenberger; David K Madtes; J Randall Curtis; Peter Cummings; Barry E Storer; Robert C Hackman Journal: Blood Date: 2003-07-17 Impact factor: 22.113
Authors: Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee Journal: J Clin Oncol Date: 2011-12-05 Impact factor: 44.544
Authors: Andrew C Harris; Rachel Young; Steven Devine; William J Hogan; Francis Ayuk; Udomsak Bunworasate; Chantiya Chanswangphuwana; Yvonne A Efebera; Ernst Holler; Mark Litzow; Rainer Ordemann; Muna Qayed; Anne S Renteria; Ran Reshef; Matthias Wölfl; Yi-Bin Chen; Steven Goldstein; Madan Jagasia; Franco Locatelli; Stephan Mielke; David Porter; Tal Schechter; Zhanna Shekhovtsova; James L M Ferrara; John E Levine Journal: Biol Blood Marrow Transplant Date: 2015-09-16 Impact factor: 5.742
Authors: G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty Journal: Bone Marrow Transplant Date: 2015-09-21 Impact factor: 5.483
Authors: Raphael Carapito; Ismail Aouadi; Angélique Pichot; Perrine Spinnhirny; Aurore Morlon; Irina Kotova; Cécile Macquin; Véronique Rolli; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Catherine Paillard; Myriam Maumy-Bertrand; Frédéric Bertrand; Peter A von dem Borne; Jürgen H E Kuball; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Dominique Charron; Mohamad Mohty; Yasuo Morishima; Gérard Socié; Seiamak Bahram Journal: Bone Marrow Transplant Date: 2020-04-14 Impact factor: 5.483